aTyr Pharma (aTyr Pharma) Interest Coverage

: N/A (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. aTyr Pharma's Operating Income for the three months ended in Dec. 2023 was $-15.96 Mil. aTyr Pharma's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. aTyr Pharma Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for aTyr Pharma's Interest Coverage or its related term are showing as below:

LIFE's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 144.99
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

aTyr Pharma Interest Coverage Historical Data

The historical data trend for aTyr Pharma's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

aTyr Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

N/A

aTyr Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Coverage																N/A	N/A	N/A	N/A	N/A

Competitive Comparison

For the Biotechnology subindustry, aTyr Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

aTyr Pharma Interest Coverage Distribution

For the Biotechnology industry and Healthcare sector, aTyr Pharma's Interest Coverage distribution charts can be found below:

* The bar in red indicates where aTyr Pharma's Interest Coverage falls into.

aTyr Pharma Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

aTyr Pharma's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, aTyr Pharma's Interest Expense was $0.00 Mil. Its Operating Income was $-54.92 Mil. And its Long-Term Debt & Capital Lease Obligation was $13.77 Mil.

GuruFocus does not calculate aTyr Pharma's interest coverage with the available data.

aTyr Pharma's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, aTyr Pharma's Interest Expense was $0.00 Mil. Its Operating Income was $-15.96 Mil. And its Long-Term Debt & Capital Lease Obligation was $13.77 Mil.

GuruFocus does not calculate aTyr Pharma's interest coverage with the available data.

The higher the ratio, the stronger the company's Financial Strength is.

aTyr Pharma (NAS:LIFE) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

aTyr Pharma Interest Coverage Related Terms

Thank you for viewing the detailed overview of aTyr Pharma's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

aTyr Pharma (aTyr Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » aTyr Pharma Inc (NAS:LIFE) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

471A:Germany

Address

10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121

Website

https://www.atyrpharma.com

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Executives

Sanjay Shukla	officer: Chief Medical Officer	C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO CA 92121
Paul Schimmel	director	88 SIDNEY ST, CAMBRIDGE MA 02139
Jill Marie Broadfoot	officer: Chief Financial Officer	3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Sara Zaknoen	director	C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
John K Clarke	director	C/O CARDINAL HEALTH PARTNERS, 221 NASSAU STREET, PRINCETON NJ 08542
Nancy Krueger	officer: See Remarks	C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Svetlana Lucas	director	3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jane A Gross	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
John Mendlein	director, officer: CEO and Executive Chairman
Ecor1 Capital Fund Qualified, L.p.	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ashraf Amanullah	officer: Vice President, Manufacturing	C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
John T Blake	officer: Vice President, Finance	C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342
Timothy P Coughlin	director	339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075
Jeffrey S. Hatfield	director	11080 ROSELLE STREET, SAN DIEGO CA 92121
David John King	officer: See Remarks	3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121